

#3 PATENT 1624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Bashiardes, et al

Examiner: TBD

**COPY OF PAPERS
ORIGINALLY FILED**

Application No.: **09 990 015**
~~09/090,025~~

Art Unit: 1624

Filed: **21 November 2001**

Title: **Preparation and Medicaments Comprising
Them**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

July 25, 2002

Date of Deposit

Bonnie Stein
Signature

Bonnie Stein



INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

RECEIVED

AUG 05 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (a) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

The items listed with an asterisk on the attached PTO-1449 (modified) have been previously cited by applicant in related application of this series:


U.S. Application No. 09/480,965

Filed January 14, 2000

File No.: ST97019US-CPA

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.


Respectfully submitted,


Irving Newman, Reg. No. 22,638
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
Aventis Docket No. ST97019US-CNT1

FORM PTO-1449
(Modified) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

ST97019US CNT1

SERIAL NO.

09/990,025

APPLICANT

Bashiardes, et al

FILING DATE

21 November 2001

GROUP

1624

TECH CENTER 1600/2900

AUG 05 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	*	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION YES NO
	*	AH 9 7 2 8 8 1 3	8/14/97	WO			

OTHER DOCUMENTS

EXAMINER INITIALS	*	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	*	AK Nishie et al.; Pharmacology of Alkyl and Hydroxyalkylpyrazines; J. TOXIC. APP. PHARM.; 17:244-249; (1970)
	*	AL Hardt et al.; Curie-Point pyrolysis-capillary gas chromatography – mass spectrometry of polyhydroxyalkylpyrazines; J. ANAL. APP. PYROL.; 13:191-198; (1999)
	*	AM Eitelman et al.; Decomposition reactions of amino sugars: the dehydration of 2-amino 2-deoxy-D-glucose; CARBOHYDRATE RESEARCH; 77:205-211; (1979)
	*	AN Tsuchida et al.; Identification of Novel Non-volatile pyrazines in commercial carmel colors; DEV. FOOD SCI.; 13:85 (1986)
	*	AO PCT/FR98/01544: International Preliminary Examination Report
	*	AP PCT/FR98/01544: International Search Report

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Note: Asterisk (*) item(s) have been previously cited in a related application(s) either by the applicant or by the USPTO and therefore copies of the reference(s) are not being submitted.